Medico Intercontinental Ltd (MIL) — shareholding pattern, promoter holding, financials and share price
About Medico Intercontinental Ltd (MIL)
Medico Intercontinental Ltd operates in the Trading & Distributors industry, within the Services sector. It trades on the NSE as MIL and on the BSE under scrip code 539938. Its ISIN is INE858Q01019.
Incorporated in 1914, Medico Intercontinental Ltd is engaged in trading of Pharmaceutical products [1]
Medico Intercontinental Limited specializes in the trading of pharmaceutical products.
The company acts as a platform for bio-pharmaceutical companies, facilitating global access to novel therapies.
Listed peers in Trading & Distributors: AA Plus Tradelink Ltd, Franklin Industries Ltd, Remedium Lifecare Ltd, Nirav Commercials Ltd, Prismx Global Ventures Ltd, Salora International Ltd.
Valuation & Returns
10 Jul 2026At ₹28.2 a share on 10 Jul 2026, Medico Intercontinental Ltd (MIL) was valued at a price-to-earnings ratio of -8.77x against an industry P/E of 21.24x and a price-to-book of 0.58x on a book value of ₹48.65 per share as of Mar 2025. Solomo computes return on equity of -22.67% and return on capital employed of -1.68% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -8.77x
- Industry P/E
- 21.24x
- P/B
- 0.58x
- EPS (TTM)
- ₹-11.03
- Book value / share
- ₹48.65
- ROE
- -22.67%
- ROCE
- -1.68%
- ROA
- -14.56%
- Debt / equity
- 0.35x
- Dividend yield
- 0%
- EBITDA margin
- 5.09%
- 52-week range
- ₹20.61 – ₹43
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Medico Intercontinental Ltd (MIL) reported revenue of ₹84 crore, net profit of ₹-11 crore and earnings per share of ₹-3.2. That compares with revenue of ₹96 crore and net profit of ₹5 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹22.49 crore and net profit ₹-2.33 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 74 | 76 | 71 | 96 | 84 |
| Net profit (₹ cr) | 3 | 4 | 4 | 5 | -11 |
| EPS (₹) | 9.54 | 3.61 | 3.95 | 5.06 | -3.2 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 106.57% | 7.42% | 19.59% | 34.56% |
| Profit growth | - | 18.07% | 25.05% | 28.10% |
| Stock price CAGR | - | -11% | -29% | -32% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 58.51% of Medico Intercontinental Ltd (MIL) (up 1.36 pp QoQ). Market capitalisation was ₹28 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2016.
Largest disclosed public shareholders in Jun 2026: HUF 4.94%, LALITA . 1.5%, DD MASTER HUF . 1.24%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 58.51% | - | - | - | 41.49% |
| Mar 2026 | 57.15% | - | - | - | 42.85% |
| Dec 2025 | 57.15% | - | - | - | 42.85% |
| Sep 2025 | 55.17% | - | - | - | 44.83% |
| Jun 2025 | 55.17% | - | - | - | 44.83% |
| Mar 2025 | 55.17% | - | - | - | 44.83% |
| Dec 2024 | 55.17% | - | - | - | 44.83% |
| Sep 2024 | 55.08% | - | - | - | 44.92% |